Akero Therapeutics, Inc.
AKRO
$42.60
-$0.25-0.58%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.93% | -32.58% | -26.89% | -83.33% | -80.12% |
| Total Depreciation and Amortization | -- | -- | 650.00% | -80.00% | -90.91% |
| Total Amortization of Deferred Charges | 18.47% | 58.93% | 45.00% | 41.38% | -65.03% |
| Total Other Non-Cash Items | 21.54% | 29.37% | 64.77% | 54.88% | 54.12% |
| Change in Net Operating Assets | 327.77% | -127.58% | -135.36% | 85.81% | -242.79% |
| Cash from Operations | 16.03% | -92.56% | -37.97% | -41.64% | -156.61% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 131.13% | -933.52% | 19.44% | 158.13% | -98.67% |
| Cash from Investing | 131.00% | -933.52% | 19.44% | 158.13% | -99.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 949.85% | 10.89% | 14,162.66% | 288.46% | -99.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -110.22% | 6.45% | -- | -7.92% |
| Cash from Financing | 2,388.67% | 7.79% | 15,037.65% | 280.52% | -100.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 111.01% | -139.60% | 168.40% | 103.27% | -268.40% |